Announced details
Regenerative medicine, specified cell-processed products, various cell-processed products
The counterparty and approval authority from which セルプロジャパン株式会社 will obtain the approval. The consolidated subsidiary appears to be the applicant.
License to Manufacture Specified Processed Cell Products
Kanto-Shinetsu Regional Bureau of Health and Welfare
Facility number FA3260003. Expiration date: Not disclosed
Shonan iPark, Block A, Building 3, 2nd Floor, Room 3021, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Specified cell-processed product manufacturing business and services |
| Counterparty | Kanto-Shinetsu Regional Bureau of Health and Welfare |
| Relationship with the Company | The counterparty and approval authority from which セルプロジャパン株式会社 will obtain the approval. The consolidated subsidiary appears to be the applicant. |
| Launch date | Full-scale rollout planned going forward (specific timing not disclosed) |
| Applicable area | Regenerative medicine, specified cell-processed products, various cell-processed products |
| Award/certification name | License to Manufacture Specified Processed Cell Products |
| Awarding / certifying body | Kanto-Shinetsu Regional Bureau of Health and Welfare |
| Registration number and expiry date | Facility number FA3260003. Expiration date: Not disclosed |
| Location | Shonan iPark, Block A, Building 3, 2nd Floor, Room 3021, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To obtain formal approval as a manufacturer of specified cell-processed products under the Act on Securing Safety of Regenerative Medicine. The company explains that it will make full-scale inroads into businesses and services covering a range of cell-processed products, leveraging the manufacturing and quality control technologies it has developed to date.